Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development ; volume:62 ; number:12 ; day:2 ; month:11 ; year:2023 ; pages:1765-1779 ; date:12.2023
Clinical pharmacokinetics ; 62, Heft 12 (2.11.2023), 1765-1779, 12.2023
- Urheber
-
Wojciechowski, Jessica
Purohit, Vivek S.
Huh, Yeamin
Banfield, Christopher
Nicholas, Timothy
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40262-023-01318-3
- URN
-
urn:nbn:de:101:1-2024021511232338654019
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:29 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Wojciechowski, Jessica
- Purohit, Vivek S.
- Huh, Yeamin
- Banfield, Christopher
- Nicholas, Timothy
- SpringerLink (Online service)
Ähnliche Objekte (12)
Midazolam Microdosing and Population Pharmacokinetic Modelling to Assess CYP3A Drug-Drug Interactions in Early Clinical Development
Clinical Evidence of Herbal Drugs As Perpetrators of Pharmacokinetic Drug Interactions
Individualization of drug therapy considering pharmacokinetic and clinical factors
Advanced population pharmacokinetic modelling to quantify selected characteristics of drugs
Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs
Ocular Drug Distribution After Topical Administration: Population Pharmacokinetic Model in Rabbits
Modern pharmacokinetic-pharmacodynamic techniques to study physiological mechanisms of pharmacokinetic drug-drug interactions and disposition of antibiotics and to assess clinical relevance
Application of population, physiologically based, and semi-physiological pharmacokinetic modeling to assess sources of pharmacokinetic variability in individual drugs
Pharmacokinetic Drug Interaction Studies with Enzalutamide
Validation of a Population Pharmacokinetic Model of Vortioxetine Using Therapeutic Drug Monitoring Data
The influence of pharmacogenetics on the clinical relevance of pharmacokinetic drug–drug interactions: drug–gene, drug–gene–gene and drug–drug–gene interactions
Clinical Pharmacokinetic Studies of Enzalutamide
Midazolam Microdosing and Population Pharmacokinetic Modelling to Assess CYP3A Drug-Drug Interactions in Early Clinical Development
Clinical Evidence of Herbal Drugs As Perpetrators of Pharmacokinetic Drug Interactions
Individualization of drug therapy considering pharmacokinetic and clinical factors
Advanced population pharmacokinetic modelling to quantify selected characteristics of drugs
Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs
Ocular Drug Distribution After Topical Administration: Population Pharmacokinetic Model in Rabbits
Modern pharmacokinetic-pharmacodynamic techniques to study physiological mechanisms of pharmacokinetic drug-drug interactions and disposition of antibiotics and to assess clinical relevance
Application of population, physiologically based, and semi-physiological pharmacokinetic modeling to assess sources of pharmacokinetic variability in individual drugs
Pharmacokinetic Drug Interaction Studies with Enzalutamide
Validation of a Population Pharmacokinetic Model of Vortioxetine Using Therapeutic Drug Monitoring Data
The influence of pharmacogenetics on the clinical relevance of pharmacokinetic drug–drug interactions: drug–gene, drug–gene–gene and drug–drug–gene interactions
Clinical Pharmacokinetic Studies of Enzalutamide
Midazolam Microdosing and Population Pharmacokinetic Modelling to Assess CYP3A Drug-Drug Interactions in Early Clinical Development
Clinical Evidence of Herbal Drugs As Perpetrators of Pharmacokinetic Drug Interactions
Individualization of drug therapy considering pharmacokinetic and clinical factors
Advanced population pharmacokinetic modelling to quantify selected characteristics of drugs
Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs
Ocular Drug Distribution After Topical Administration: Population Pharmacokinetic Model in Rabbits
Modern pharmacokinetic-pharmacodynamic techniques to study physiological mechanisms of pharmacokinetic drug-drug interactions and disposition of antibiotics and to assess clinical relevance
Application of population, physiologically based, and semi-physiological pharmacokinetic modeling to assess sources of pharmacokinetic variability in individual drugs
Pharmacokinetic Drug Interaction Studies with Enzalutamide
Validation of a Population Pharmacokinetic Model of Vortioxetine Using Therapeutic Drug Monitoring Data
The influence of pharmacogenetics on the clinical relevance of pharmacokinetic drug–drug interactions: drug–gene, drug–gene–gene and drug–drug–gene interactions